Dimethyl Fumarate for Treatment of Multiple Sclerosis: Mechanism of Action, Effectiveness, and Side Effects
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dimethyl Fumarate for Treatment of Multiple Sclerosis: Mechanism of Action, Effectiveness, and Side Effects
Authors
Keywords
Multiple sclerosis, Neuroinflammation, Oral, Immunotherapy, Neuroprotection, Clinical trial, Dimethyl fumarate, Effectiveness, Side effects
Journal
Current Neurology and Neuroscience Reports
Volume 13, Issue 11, Pages -
Publisher
Springer Nature
Online
2013-09-23
DOI
10.1007/s11910-013-0394-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
- (2013) Bob W. van Oosten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Manufacturer's Response to Case Reports of PML
- (2013) Marianne T. Sweetser et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient Treated with Fumaric Acid
- (2013) Ummehan Ermis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of dimethyl fumarate on neuroprotection and immunomodulation
- (2012) Philipp Albrecht et al. Journal of Neuroinflammation
- Fatal PML associated with efalizumab therapy: Insights into integrin L 2 in JC virus control
- (2012) N. Schwab et al. NEUROLOGY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
- Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action
- (2011) R. Gold et al. CLINICAL IMMUNOLOGY
- Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
- (2011) Kamran Ghoreschi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study
- (2011) Ludwig Kappos et al. Multiple Sclerosis Journal
- Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
- (2011) Gisa Ellrichmann et al. PLoS One
- The Nrf2-ARE Pathway
- (2010) Jeffrey A. Johnson et al. Annals of the New York Academy of Sciences
- Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions
- (2010) Jack van Horssen et al. FREE RADICAL BIOLOGY AND MEDICINE
- BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis
- (2010) D. G. MacManus et al. JOURNAL OF NEUROLOGY
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
- (2008) Ludwig Kappos et al. LANCET
- Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: Implications for multiple sclerosis
- (2008) Eva Herrero-Herranz et al. NEUROBIOLOGY OF DISEASE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started